ISSN 2149-2247 | E-ISSN 2149-2549
Original Article
Effectiveness and Safety of Clonazepam, Pregabalin, and Alpha Lipoic Acid for the Treatment of Burning Mouth Syndrome
1 Department of Dermatology, Erciyes University School of Medicine, Kayseri, Turkey  
2 Department of Dentistry, Erciyes University School of Dentistry, Kayseri, Turkey  
Erciyes Med J 2018; 40: 35-38
DOI: 10.5152/etd.2018.17160
Key Words: Alpha lipoic acid, burning mouth syndrome, clonazepam, pregabalin, visual analog scale
Abstract

 

Objective: Burning mouth syndrome is characterized by pain in the oral mucosa with no visible organic pathology. Few treatment options are available; however, none of them are gold-standard. Here we evaluated the effectiveness and safety of clonazepam, pregabalin, and alpha lipoic acid for treating burning mouth syndrome.

 

Materials and Methods: Patients were divided into three groups. Clonazepam (2 mg/day) was administered to the patients in the first group, pregabalin (150 mg/day) to those in the second group, and alpha lipoic acid (600 mg/day) to those in the third group. Each group consisted of 30 patients. The intensity of oral pain in each group was measured before and at the end of the treatment (fourth month) using the visual analog scale. The study was carried on for four months.

 

Results: Significant improvement was observed in the clonazepam and pregabalin groups; no effects were observed in the alpha lipoic acid group. No serious side effects were noted in any of the patients.

 

Conclusion: Systemic clonazepam and pregabalin are viable options for the treatment of burning mouth syndrome.

 

Cite this article as: Çınar SL, Kartal D, Pergel T, Borlu M. Effectiveness and Safety of Clonazepam, Pregabalin, and Alpha Lipoic Acid for the Treatment of Burning Mouth Syndrome. Erciyes Med J 2018; 40(1): 35-8.

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2018 Erciyes University Faculty of Medicine | Latest Update: 03.10.2018